Here’s Why Investors Are Piling Into These Five Stocks

Sientra Inc (NASDAQ:SIEN) shares are 9% higher today on word that third party testers found the company’s medical implants safe and without substantial risk to patients. Sientra Inc (NASDAQ:SIEN) suspended sales of its implants in October, citing technical compliance difficulties at the company’s Brazilian contract manufacture facility. If the FDA agrees with the third party testers, the company will have its devices back on the market again. Of the around 730 elite funds we track, 10 funds owned $58.11 million worth of Sientra shares (accounting for 38.20% of the float) on September 30, versus six funds and $129.77 million, respectively, a quarter earlier.

Investors have sent Athersys, Inc. (NASDAQ:ATHX)‘s stock by more than 20% today on the news that the company entered into a partnership with Healios. Under the terms of the deal, Healios will receive exclusive rights for the development of MultiStem for treating ischemic stroke in Japan and will also get an exclusive option for development of two additional MultiStem clinical indications in Japan, including the treatment of Acute Respiratory Distress Syndrome and another indication in the orthopaedic area. In exchange, Athersys, Inc. (NASDAQ:ATHX) will receive a license fee of $15 million and is eligible for additional milestone and royalty payments based on various development and commercialization metrics.

Ardelyx Inc (NASDAQ:ARDX)‘s shares bounced back by 4% in afternoon trading after its stock cratered by more than 32% yesterday. Investors are buying because they think the big sell-off due to Ardelyx Inc (NASDAQ:ARDX)’s announcement that it will do a secondary offering of 7.5 million shares at $10 per unit is a bit over-done. Seven funds among those we track owned shares of the company at the end of September. That’s down from 10 funds a quarter earlier.

Disclosure: none